Prof. Dr. Pham Manh Hung, Chairman of the Southeast Asian Heart and Stroke Federation, commented at the scientific conference "Semaglutide - The key to opening a new era in the treatment of type 2 diabetes" recently organized by the Center for Medical Human Resources Training under Social Needs (CHPT) under Ho Chi Minh City University of Medicine and Pharmacy in coordination with Novo Nordisk Vietnam Company.
The burden of disease overlaps with type 2 diabetes
In Vietnam, the rate of type 2 diabetes is on the rise. However, it is estimated that nearly 2/3 of people with DTT have not yet achieved the target of controlling blood sugar (HbA1
Experts also commented that individual blood sugar control has not brought optimal results to prevent the progression of the disease. Research on blood sugar control in people with type 2 diabetes treated as outpatients at Gia Dinh People's Hospital shows that although blood sugar control plays a key role in preventing complications of small blood vessels, the effectiveness of large blood vessel complications is still limited.
In addition, according to the American Diabetes Association (ADA), weight management is also a targeted intervention, providing other benefits besides blood sugar to improve risk factors for metabolic heart disease and quality of life.
Therefore, the multifaceted management direction is a pillar in the treatment regimen, helping to prevent disease "turns", reduce economic burdens and improve the lives of patients, help patients live healthier, maintain normal life.
GLP-1 RA Semaglutide: Comprehensive care for people with type 2 diabetes
At the conference, domestic and international experts shared and discussed research results and clinical experience on GLP-1 RA (Semaglutide) trans fading therapy in the treatment of type 2 diabetes. This is a therapy to help control multiple factors sustainably, including controlling blood sugar, reducing cardiovascular events and controlling weight, opening up a comprehensive approach to controlling type 2 diabetes in Vietnam.
Dr.BS. Nguyen Quang Bay - Head of the Department of Endocrinology - Diabetes, Bach Mai Hospital - shared: "New medical advances such as GLP-1 RA Semaglutide therapy with many outstanding advantages such as good blood sugar control, weight loss and especially the effectiveness of protecting multiple organs, including the heart and kidneys. The drug has a long history of effect, only needs to be injected once a week, and can be combined with other DTD treatment drugs, so patients can easily comply. Therefore, Semaglutide can help people with type 2 diabetes get closer to the desire to have a healthy, almost normal life.
---
*The content is provided by the Center for Social Needs Medical Human Resources Training (CHPT) to raise awareness of type 2 diabetes, not a replacement for doctor's consultation.
